Physician profile
Anthanasios James Foster
NPI 1871572156
$2,390.64
in general payments reported to CMS, 2019-2025
26 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $134 · 2021: $300 · 2022: $163 · 2023: $117 · 2024: $432 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $322.92 | 2019-2025 | |
| Glaxosmithkline, LLC. | $233.51 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $218.73 | 2019-2025 | |
| Novo Nordisk INC | $193.49 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $186.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $167.52 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $142.24 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $125.15 | 2024-2025 | |
| Amgen INC. | $90.24 | 2022-2025 | Evenity, Prolia, Prolia |
| Exact Sciences Corporation | $82.50 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $80.46 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.00 | 2024-2025 | Xifaxan, Trulance |
| Almatica Pharma LLC | $57.62 | 2025 | Loreev Xr |
| Abbott Laboratories | $50.07 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $46.19 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $45.40 | 2019 | |
| Inspire Medical Systems, INC. | $44.92 | 2024 | Inspire |
| Antares Pharma, INC. | $42.37 | 2019-2020 | |
| Abiomed | $39.63 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $36.36 | 2019-2025 | Airsupra |
| Gilead Sciences, INC. | $25.29 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.16 | 2022 | |
| Phadia US INC. | $20.47 | 2022 | |
| Therapeuticsmd, INC. | $16.71 | 2019 | |
| Daiichi Sankyo INC. | $14.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthanasios Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.